# TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma

> **NCT04059224** · PHASE2 · COMPLETED · sponsor: **Universitair Ziekenhuis Brussel** · enrollment: 45 (actual)

## Conditions studied

- Stage IV Melanoma
- Stage III Melanoma

## Interventions

- **DRUG:** Trametinib
- **DRUG:** Dabrafenib

## Key facts

- **NCT ID:** NCT04059224
- **Lead sponsor:** Universitair Ziekenhuis Brussel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-28
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04059224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04059224, "TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04059224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*